JP2014520822A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014520822A5 JP2014520822A5 JP2014519378A JP2014519378A JP2014520822A5 JP 2014520822 A5 JP2014520822 A5 JP 2014520822A5 JP 2014519378 A JP2014519378 A JP 2014519378A JP 2014519378 A JP2014519378 A JP 2014519378A JP 2014520822 A5 JP2014520822 A5 JP 2014520822A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- aliphatic
- aryl
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 112
- 125000000623 heterocyclic group Chemical group 0.000 claims description 110
- 125000003118 aryl group Chemical group 0.000 claims description 109
- 125000001072 heteroaryl group Chemical group 0.000 claims description 91
- 125000003545 alkoxy group Chemical group 0.000 claims description 78
- 150000001875 compounds Chemical class 0.000 claims description 56
- 229910052801 chlorine Inorganic materials 0.000 claims description 54
- 229910052731 fluorine Inorganic materials 0.000 claims description 54
- 229910052799 carbon Inorganic materials 0.000 claims description 50
- -1 hydroxy, amino Chemical group 0.000 claims description 50
- 229910052739 hydrogen Inorganic materials 0.000 claims description 43
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims description 42
- 125000001931 aliphatic group Chemical group 0.000 claims description 42
- 229910052760 oxygen Inorganic materials 0.000 claims description 42
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 40
- 125000006719 (C6-C10) aryl (C1-C6) alkyl group Chemical group 0.000 claims description 36
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 36
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 36
- 229910052717 sulfur Inorganic materials 0.000 claims description 36
- 229910052757 nitrogen Inorganic materials 0.000 claims description 35
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 34
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 30
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 30
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 30
- 125000004104 aryloxy group Chemical group 0.000 claims description 29
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 28
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 26
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims description 26
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 24
- 125000001769 aryl amino group Chemical group 0.000 claims description 21
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 20
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 20
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims description 17
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 17
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 16
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 15
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 14
- 125000005947 C1-C6 alkylsulfonyloxy group Chemical group 0.000 claims description 14
- 125000005256 alkoxyacyl group Chemical group 0.000 claims description 14
- 125000005138 alkoxysulfonyl group Chemical group 0.000 claims description 14
- 125000005257 alkyl acyl group Chemical group 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 125000003003 spiro group Chemical group 0.000 claims description 14
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 13
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 12
- 125000006621 (C3-C8) cycloalkyl-(C1-C6) alkyl group Chemical group 0.000 claims description 12
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 12
- 125000001188 haloalkyl group Chemical group 0.000 claims description 12
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 12
- 125000005241 heteroarylamino group Chemical group 0.000 claims description 12
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 11
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 10
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims description 10
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 125000000304 alkynyl group Chemical group 0.000 claims description 9
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 claims description 9
- 235000008206 alpha-amino acids Nutrition 0.000 claims description 9
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims description 9
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 9
- 125000002619 bicyclic group Chemical group 0.000 claims description 9
- 125000005114 heteroarylalkoxy group Chemical group 0.000 claims description 9
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 7
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims description 7
- 125000002757 morpholinyl group Chemical group 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims description 6
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims description 6
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 6
- 125000003282 alkyl amino group Chemical group 0.000 claims description 6
- 125000003386 piperidinyl group Chemical group 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 150000001204 N-oxides Chemical class 0.000 claims description 5
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 5
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 4
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 125000006625 (C3-C8) cycloalkyloxy group Chemical group 0.000 claims description 3
- 125000004450 alkenylene group Chemical group 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 3
- 239000002207 metabolite Substances 0.000 claims description 3
- 230000003287 optical effect Effects 0.000 claims description 3
- 239000000651 prodrug Substances 0.000 claims description 3
- 229940002612 prodrug Drugs 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 108010050904 Interferons Proteins 0.000 claims 4
- 102000014150 Interferons Human genes 0.000 claims 4
- 229940079322 interferon Drugs 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 101710200424 Inosine-5'-monophosphate dehydrogenase Proteins 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 102000005741 Metalloproteases Human genes 0.000 claims 2
- 108010006035 Metalloproteases Proteins 0.000 claims 2
- 108060004795 Methyltransferase Proteins 0.000 claims 2
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 claims 2
- 101800001019 Non-structural protein 4B Proteins 0.000 claims 2
- 101800001014 Non-structural protein 5A Proteins 0.000 claims 2
- 102000012479 Serine Proteases Human genes 0.000 claims 2
- 108010022999 Serine Proteases Proteins 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 claims 1
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 229940124186 Dehydrogenase inhibitor Drugs 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims 1
- HAEJPQIATWHALX-KQYNXXCUSA-N ITP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(N=CNC2=O)=C2N=C1 HAEJPQIATWHALX-KQYNXXCUSA-N 0.000 claims 1
- 102100040018 Interferon alpha-2 Human genes 0.000 claims 1
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 1
- JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 claims 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- JZKXXXDKRQWDET-QMMMGPOBSA-N L-m-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC(O)=C1 JZKXXXDKRQWDET-QMMMGPOBSA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 claims 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- 108010077895 Sarcosine Proteins 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 230000005867 T cell response Effects 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 1
- 229960003805 amantadine Drugs 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 claims 1
- 229960000517 boceprevir Drugs 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- FKRSSPOQAMALKA-CUPIEXAXSA-N daclatasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2N=C(NC=2)[C@H]2N(CCC2)C(=O)[C@@H](NC(=O)OC)C(C)C)=CN1 FKRSSPOQAMALKA-CUPIEXAXSA-N 0.000 claims 1
- 229960005449 daclatasvir Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 108700003601 dimethylglycine Proteins 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 235000004554 glutamine Nutrition 0.000 claims 1
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 229960002591 hydroxyproline Drugs 0.000 claims 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 1
- 229960002751 imiquimod Drugs 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000002452 interceptive effect Effects 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 230000009545 invasion Effects 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- JZKXXXDKRQWDET-UHFFFAOYSA-N meta-tyrosine Natural products OC(=O)C(N)CC1=CC=CC(O)=C1 JZKXXXDKRQWDET-UHFFFAOYSA-N 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 229940078490 n,n-dimethylglycine Drugs 0.000 claims 1
- 229960003104 ornithine Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 235000013930 proline Nutrition 0.000 claims 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- 229960000888 rimantadine Drugs 0.000 claims 1
- 229940043230 sarcosine Drugs 0.000 claims 1
- 235000004400 serine Nutrition 0.000 claims 1
- BBAWEDCPNXPBQM-GDEBMMAJSA-N telaprevir Chemical compound N([C@H](C(=O)N[C@H](C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C1CCCCC1)C(=O)C1=CN=CC=N1 BBAWEDCPNXPBQM-GDEBMMAJSA-N 0.000 claims 1
- 229960002935 telaprevir Drugs 0.000 claims 1
- 108010017101 telaprevir Proteins 0.000 claims 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 235000014393 valine Nutrition 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 0 N=*C1=CCCCC=CCC2CC1C2 Chemical compound N=*C1=CCCCC=CCC2CC1C2 0.000 description 26
- 125000004122 cyclic group Chemical group 0.000 description 6
- MVHOAOSHABGEFL-UHFFFAOYSA-N Cc1nc(cc(C)cc2)c2[nH]1 Chemical compound Cc1nc(cc(C)cc2)c2[nH]1 MVHOAOSHABGEFL-UHFFFAOYSA-N 0.000 description 4
- LLPKQRMDOFYSGZ-UHFFFAOYSA-N Cc1cnc(C)[nH]1 Chemical compound Cc1cnc(C)[nH]1 LLPKQRMDOFYSGZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FRXLGXNJLKYPBM-UHFFFAOYSA-N Cc1nc(ccc(-c2ccc(C)cc2)c2)c2[nH]1 Chemical compound Cc1nc(ccc(-c2ccc(C)cc2)c2)c2[nH]1 FRXLGXNJLKYPBM-UHFFFAOYSA-N 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- NNETVVVKJRQFFF-UHFFFAOYSA-N CC(C)=NC(C)=N Chemical compound CC(C)=NC(C)=N NNETVVVKJRQFFF-UHFFFAOYSA-N 0.000 description 1
- RAPTZNFAMIHBTG-UHFFFAOYSA-N CC(C)CC(N1CCCC1)=O Chemical compound CC(C)CC(N1CCCC1)=O RAPTZNFAMIHBTG-UHFFFAOYSA-N 0.000 description 1
- XHVZYDYZAWTRNC-VUWPPUDQSA-N CC(C)[C@@H](C(N1CC2(CC2)CC1)O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N1CC2(CC2)CC1)O)NC(OC)=O XHVZYDYZAWTRNC-VUWPPUDQSA-N 0.000 description 1
- WXPDONXQEMHKRQ-SHUZPENHSA-N CC(C)[C@@H](C(N1[C@H](c2ncc(-c(c3c4CC5(CCCC5)C3)ccc4-c(cc3)ccc3-c3cnc(C=C)[nH]3)[nH]2)SCC1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N1[C@H](c2ncc(-c(c3c4CC5(CCCC5)C3)ccc4-c(cc3)ccc3-c3cnc(C=C)[nH]3)[nH]2)SCC1)=O)NC(OC)=O WXPDONXQEMHKRQ-SHUZPENHSA-N 0.000 description 1
- ZPDGQGUHCOIMBK-ZCFIWIBFSA-N CC(C)[C@@H](C)NC=O Chemical compound CC(C)[C@@H](C)NC=O ZPDGQGUHCOIMBK-ZCFIWIBFSA-N 0.000 description 1
- GINNNRQOBSAUHS-UHFFFAOYSA-N CC(CC1)CCC1c1cnc(C)[nH]1 Chemical compound CC(CC1)CCC1c1cnc(C)[nH]1 GINNNRQOBSAUHS-UHFFFAOYSA-N 0.000 description 1
- YICAMJWHIUMFDI-UHFFFAOYSA-N CC(Nc1ccc(C)cc1)=O Chemical compound CC(Nc1ccc(C)cc1)=O YICAMJWHIUMFDI-UHFFFAOYSA-N 0.000 description 1
- TVSMLBGFGKLKOO-UHFFFAOYSA-N CC1CCN(C)CC1 Chemical compound CC1CCN(C)CC1 TVSMLBGFGKLKOO-UHFFFAOYSA-N 0.000 description 1
- ZEBFPAXSQXIPNF-UHFFFAOYSA-N CC1NC(C)CC1 Chemical compound CC1NC(C)CC1 ZEBFPAXSQXIPNF-UHFFFAOYSA-N 0.000 description 1
- LIWSUETYYMPTRY-IAXJKZSUSA-N CCO[C@@](CC1)(CN1C(C(C(C)C)NC(OC)=O)=O)OC Chemical compound CCO[C@@](CC1)(CN1C(C(C(C)C)NC(OC)=O)=O)OC LIWSUETYYMPTRY-IAXJKZSUSA-N 0.000 description 1
- RXYPXQSKLGGKOL-UHFFFAOYSA-N CN1CCN(C)CC1 Chemical compound CN1CCN(C)CC1 RXYPXQSKLGGKOL-UHFFFAOYSA-N 0.000 description 1
- DTZQNEGIDKMTEN-UHFFFAOYSA-N COC(NCCN(CC1(CC1)C1)C1c1ncc(-c(cc2)ccc2-c(c2c3CC4(CCCC4)C2)ccc3-c(cc2)ccc2-c2cnc[nH]2)[nH]1)=O Chemical compound COC(NCCN(CC1(CC1)C1)C1c1ncc(-c(cc2)ccc2-c(c2c3CC4(CCCC4)C2)ccc3-c(cc2)ccc2-c2cnc[nH]2)[nH]1)=O DTZQNEGIDKMTEN-UHFFFAOYSA-N 0.000 description 1
- DMJJJHIFADRWEF-UHFFFAOYSA-N Cc([nH]1)nc2c1nc(C)cc2 Chemical compound Cc([nH]1)nc2c1nc(C)cc2 DMJJJHIFADRWEF-UHFFFAOYSA-N 0.000 description 1
- GHKLCVJTEJBCBX-UHFFFAOYSA-N Cc([nH]c1c2)nc1cc1c2cc(C)cc1 Chemical compound Cc([nH]c1c2)nc1cc1c2cc(C)cc1 GHKLCVJTEJBCBX-UHFFFAOYSA-N 0.000 description 1
- SDXAWLJRERMRKF-UHFFFAOYSA-N Cc1cc(C)n[nH]1 Chemical compound Cc1cc(C)n[nH]1 SDXAWLJRERMRKF-UHFFFAOYSA-N 0.000 description 1
- CAVYFFVMODYNTB-UHFFFAOYSA-N Cc1ccc(-c2cnc(C)[nH]2)[s]1 Chemical compound Cc1ccc(-c2cnc(C)[nH]2)[s]1 CAVYFFVMODYNTB-UHFFFAOYSA-N 0.000 description 1
- UWXXUKDLTRPMMF-UHFFFAOYSA-N Cc1nc(COc2c-3ccc(C)c2)c-3[nH]1 Chemical compound Cc1nc(COc2c-3ccc(C)c2)c-3[nH]1 UWXXUKDLTRPMMF-UHFFFAOYSA-N 0.000 description 1
- RYBQCQMZQAUIQN-UHFFFAOYSA-N Cc1nc(ccc2c3ccc(C)c2)c3[nH]1 Chemical compound Cc1nc(ccc2c3ccc(C)c2)c3[nH]1 RYBQCQMZQAUIQN-UHFFFAOYSA-N 0.000 description 1
- BHTLHVMHQVCJCE-UHFFFAOYSA-N Cc1nc(cnc(C)c2)c2[nH]1 Chemical compound Cc1nc(cnc(C)c2)c2[nH]1 BHTLHVMHQVCJCE-UHFFFAOYSA-N 0.000 description 1
- LZSXKOQVSYULPZ-UHFFFAOYSA-N Cc1nc2cc(C)cnc2[nH]1 Chemical compound Cc1nc2cc(C)cnc2[nH]1 LZSXKOQVSYULPZ-UHFFFAOYSA-N 0.000 description 1
- RYCGXZAXJPAXDX-UHFFFAOYSA-N Cc1ncc(-c2ccc(C)cc2)[nH]1 Chemical compound Cc1ncc(-c2ccc(C)cc2)[nH]1 RYCGXZAXJPAXDX-UHFFFAOYSA-N 0.000 description 1
- ZTPXKLMKGWAUMQ-UHFFFAOYSA-N Cc1ncc(-c2ccc(cc(C)cc3)c3c2)[nH]1 Chemical compound Cc1ncc(-c2ccc(cc(C)cc3)c3c2)[nH]1 ZTPXKLMKGWAUMQ-UHFFFAOYSA-N 0.000 description 1
- BGDOKDIEVXQWSS-UHFFFAOYSA-N Cc1ncc(C(CC2)C=NC3=C2[I]=CC(C)=C3)[nH]1 Chemical compound Cc1ncc(C(CC2)C=NC3=C2[I]=CC(C)=C3)[nH]1 BGDOKDIEVXQWSS-UHFFFAOYSA-N 0.000 description 1
- WDEGVMDTYMVHTC-UHFFFAOYSA-N Cc1ncc(C2CCN(C)CC2)[nH]1 Chemical compound Cc1ncc(C2CCN(C)CC2)[nH]1 WDEGVMDTYMVHTC-UHFFFAOYSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110195113 | 2011-07-09 | ||
| CN201110195113.8 | 2011-07-09 | ||
| PCT/CN2012/000945 WO2013007106A1 (zh) | 2011-07-09 | 2012-07-09 | 作为丙型肝炎病毒抑制剂的螺环化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014520822A JP2014520822A (ja) | 2014-08-25 |
| JP2014520822A5 true JP2014520822A5 (cg-RX-API-DMAC7.html) | 2015-06-18 |
Family
ID=47442590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014519378A Pending JP2014520822A (ja) | 2011-07-09 | 2012-07-09 | Ｃ型肝炎ウイルス阻害剤としてのスピロ化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9303061B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2730572B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2014520822A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140053166A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102863428B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012283609B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014000563A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2841095A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI482766B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013007106A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP3495366A1 (en) * | 2011-07-15 | 2019-06-12 | Shionogi & Co., Ltd | Azabenzimidazole derivative having ampk-activating activity |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TWI610916B (zh) * | 2012-08-03 | 2018-01-11 | 廣東東陽光藥業有限公司 | 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用 |
| TW201412709A (zh) * | 2012-09-28 | 2014-04-01 | Sunshine Lake Pharma Co Ltd | 作為丙型肝炎抑制劑的螺環化合物及其在藥物中的應用 |
| TWI585082B (zh) * | 2012-11-29 | 2017-06-01 | 廣東東陽光藥業有限公司 | 作爲丙型肝炎抑制劑的螺環化合物、藥物組合物及它們的用途 |
| TW201439060A (zh) * | 2013-02-27 | 2014-10-16 | Sunshine Lake Pharma Co Ltd | 作爲丙型肝炎抑制劑的橋環化合物及其藥物組合物和用途 |
| CN105837561B (zh) * | 2013-06-06 | 2019-06-28 | 上海爱博医药科技有限公司 | 抑制丙肝病毒的化合物、药物组合物及其应用 |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| CN105530933B (zh) | 2013-07-17 | 2018-12-11 | 百时美施贵宝公司 | 用于治疗hcv的包含联苯衍生物的组合产品 |
| US9738629B2 (en) | 2014-01-23 | 2017-08-22 | Sunshine Lake Pharma Co., Ltd. | Bridged ring compounds as Hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof |
| CN104860931A (zh) * | 2014-02-21 | 2015-08-26 | 常州寅盛药业有限公司 | 丙肝病毒抑制剂及其制药用途 |
| CN105085493A (zh) * | 2014-04-15 | 2015-11-25 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的螺环化合物及其在药物中的应用 |
| WO2015184644A1 (zh) * | 2014-06-06 | 2015-12-10 | 爱博新药研发(上海)有限公司 | 抑制丙肝病毒的化合物、药物组合物及其应用 |
| US10100027B2 (en) | 2014-09-26 | 2018-10-16 | Changzhou Yinsheng Pharmaceutical Co., Ltd. | Benzofuran analogue as NS4B inhibitor |
| US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN106432195B (zh) * | 2015-08-12 | 2020-01-14 | 杭州民生药物研究院有限公司 | 一种制备(r)-2-(2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺的方法 |
| CN105461701A (zh) * | 2015-12-14 | 2016-04-06 | 上海步越化工科技有限公司 | 一种抗丙肝新药达卡他韦新的合成方法 |
| CN105622583A (zh) * | 2015-12-22 | 2016-06-01 | 苏州步跃医药科技有限公司 | 一种抗丙肝新药达卡他韦新的制备方法 |
| CN112225778A (zh) * | 2020-10-26 | 2021-01-15 | 辰欣药业股份有限公司 | 一种马来酸依那普利的制备方法 |
| CN116120272A (zh) * | 2022-12-31 | 2023-05-16 | 淮北师范大学 | 一种合成咯菌腈中间体2,2-二氟-1,3-苯并二噁茂-4-甲醛的方法 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2999098A (en) * | 1957-11-13 | 1961-09-05 | Universal Oil Prod Co | Bis-halocycloalkenyl derivatives of alkylidenedioxybenzenes |
| FR2707982B1 (fr) * | 1993-07-20 | 1995-09-01 | Adir | Nouveaux dérivés de benzospiroalcène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
| US8303944B2 (en) | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2709784A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US7704992B2 (en) * | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN104163816A (zh) | 2008-12-03 | 2014-11-26 | 普雷西迪奥制药公司 | Hcv ns5a的抑制剂 |
| US8314135B2 (en) | 2009-02-09 | 2012-11-20 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole antivirals |
| US8426458B2 (en) | 2009-02-27 | 2013-04-23 | Enanta Pharmaceuticals, Inc. | Hepatitis C Virus inhibitors |
| MY169311A (en) | 2009-03-27 | 2019-03-21 | Merck Sharp & Dohme | Inhibitors of hepatitis c virus replication |
| EP2410841A4 (en) | 2009-03-27 | 2012-10-24 | Presidio Pharmaceuticals Inc | SUBSTITUTED BICYCLIC HCV INHIBITORS |
| MX2011010132A (es) | 2009-03-27 | 2011-10-14 | Presidio Pharmaceuticals Inc | Inhibidores de anillo fusionado de hepatitis c. |
| US8796466B2 (en) * | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2010120935A1 (en) * | 2009-04-15 | 2010-10-21 | Abbott Laboratories | Anti-viral compounds |
| WO2010132538A1 (en) | 2009-05-12 | 2010-11-18 | Schering Corporation | Fused tricyclic aryl compounds useful for the treatment of viral diseases |
| KR20180028070A (ko) | 2009-05-13 | 2018-03-15 | 길리애드 파마셋 엘엘씨 | 항바이러스 화합물 |
| PT2432760E (pt) * | 2009-05-18 | 2013-10-21 | Actelion Pharmaceuticals Ltd | Derivados de espiro [2,4] heptano ligados em ponte como agonistas do receptor fprl2 e/ou receptor alx |
| AU2010253790A1 (en) | 2009-05-29 | 2011-12-15 | Merck Sharp & Dohme Corp. | Antiviral compounds composed of three aligned aryl moieties to treat diseases such as Hepatitis C |
| US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
| US8221737B2 (en) | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| WO2011004276A1 (en) | 2009-07-06 | 2011-01-13 | Pfizer Limited | Hepatitis c virus inhibitors |
| EP2454254A2 (en) * | 2009-07-16 | 2012-05-23 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of flavivirus infections |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| WO2011066241A1 (en) | 2009-11-25 | 2011-06-03 | Schering Corporation | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
| NZ600608A (en) | 2009-12-18 | 2015-01-30 | Idenix Pharmaceuticals Inc | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
| CA2785488A1 (en) | 2009-12-22 | 2011-07-21 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases |
| CA2784036A1 (en) | 2009-12-24 | 2011-06-30 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| CA2794181A1 (en) | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| MX2012010918A (es) | 2010-03-24 | 2013-01-18 | Vertex Pharma | Analogos para el tratamiento o prevencion de infecciones por flavivirus. |
| US20110312996A1 (en) | 2010-05-17 | 2011-12-22 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| US8877707B2 (en) | 2010-05-24 | 2014-11-04 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
| AR081848A1 (es) | 2010-06-09 | 2012-10-24 | Presidio Pharmaceuticals Inc | Inhibidores de la proteina ns5a del vhc |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| WO2012003642A1 (en) | 2010-07-09 | 2012-01-12 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and use thereof for treating viral diseases |
| BR112013002122A2 (pt) | 2010-07-26 | 2016-09-20 | Janssen R&D Ireland | derivados hetero-bicíclicos como inibidores de hcv |
| CA2805440A1 (en) | 2010-07-26 | 2012-02-09 | Merck Sharp & Dohme Corp. | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases |
| US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| WO2012020036A1 (en) | 2010-08-13 | 2012-02-16 | F. Hoffmann-La Roche Ag | Hepatitis c virus inhibitors |
| WO2012040923A1 (en) | 2010-09-29 | 2012-04-05 | Merck Sharp & Dohme Corp. | Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases |
| BR112013007696A2 (pt) | 2010-09-29 | 2019-09-24 | Merck Sharp & Dohme | composto, composição farmacêutica, usos do referido composto e da referida composição |
| JP2013540122A (ja) | 2010-09-29 | 2013-10-31 | メルク・シャープ・エンド・ドーム・コーポレイション | 縮合四環式化合物誘導体およびウィルス疾患治療のためのそれの使用方法 |
| WO2012040924A1 (en) | 2010-09-29 | 2012-04-05 | Merck Sharp & Dohme Corp. | Fused tetracyclic heterocycle compounds and methods of use thereof for treatment of viral diseases |
| WO2012050918A2 (en) | 2010-09-29 | 2012-04-19 | Presidio Pharmaceutical, Inc. | Tricyclic fused ring inhibitors of hepatitis c |
| EP2621932A4 (en) | 2010-09-29 | 2014-03-26 | Merck Sharp & Dohme | TETRACYCLIC HETEROCYCLUS COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS |
| US8841275B2 (en) * | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
| EP2651920A4 (en) | 2010-12-15 | 2014-12-17 | Abbvie Inc | ANTI-VIRAL COMPOUNDS |
| EP2651926A4 (en) | 2010-12-15 | 2014-07-09 | Abbvie Inc | ANTI-VIRAL COMPOUNDS |
| CA2821973A1 (en) | 2010-12-16 | 2012-06-21 | Abbvie Inc. | Anti-viral compounds |
| WO2012122716A1 (en) | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases |
| WO2013022810A1 (en) | 2011-08-08 | 2013-02-14 | Glaxosmithkline Llc | Chemical compounds |
| PH12014500311A1 (en) | 2011-08-08 | 2014-03-31 | Lupin Ltd | Antiviral compounds with a fused tricyclic ring |
| KR20210043734A (ko) | 2011-11-16 | 2021-04-21 | 길리애드 파마셋 엘엘씨 | 항바이러스성 화합물로서의 축합된 이미다졸릴이미다졸 |
| AU2012360905B2 (en) | 2011-12-28 | 2017-04-27 | Janssen Sciences Ireland Uc | Hetero-bicyclic derivatives as HCV inhibitors |
| NZ628515A (en) | 2012-02-10 | 2016-06-24 | Lupin Ltd | Antiviral compounds with a dibenzooxaheterocycle moiety |
-
2012
- 2012-07-09 CN CN201210239748.8A patent/CN102863428B/zh active Active
- 2012-07-09 JP JP2014519378A patent/JP2014520822A/ja active Pending
- 2012-07-09 WO PCT/CN2012/000945 patent/WO2013007106A1/zh not_active Ceased
- 2012-07-09 TW TW101124685A patent/TWI482766B/zh not_active IP Right Cessation
- 2012-07-09 US US14/130,320 patent/US9303061B2/en not_active Expired - Fee Related
- 2012-07-09 CA CA2841095A patent/CA2841095A1/en not_active Abandoned
- 2012-07-09 BR BR112014000563-0A patent/BR112014000563A2/pt not_active Application Discontinuation
- 2012-07-09 KR KR1020147002974A patent/KR20140053166A/ko not_active Withdrawn
- 2012-07-09 EP EP12811420.4A patent/EP2730572B1/en not_active Not-in-force
- 2012-07-09 AU AU2012283609A patent/AU2012283609B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014520822A5 (cg-RX-API-DMAC7.html) | ||
| ES2449540T3 (es) | Inhibidores macrocíclicos del virus de la hepatitis C | |
| ES2555230T3 (es) | Productos intermedios para la preparación de inhibidores macrocíclicos del virus de la hepatitis C | |
| ES2640063T3 (es) | Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis B | |
| ES2470568T3 (es) | Inhibidores macroc�clicos del virus de la hepatitis C | |
| ES2670984T3 (es) | Composiciones y métodos para modular receptores X farnesoides | |
| ES2761824T3 (es) | Compuestos de carboximidamida de benzimidazol y imidazopiridina que tienen actividad como inhibidores de indoleamina 2,3-dioxigenasa | |
| RU2015107043A (ru) | Соединенные циклические соединения как ингибиторы вируса гепатита с (вгс) и их фармацевтическое применение | |
| ES2359939T3 (es) | Inhibidores macrocíclicos del virus de la hepatitis c. | |
| JP2010508361A5 (cg-RX-API-DMAC7.html) | ||
| ES2541660T3 (es) | Inhibidores del VHC macrocíclicos sustituidos con pirimidina | |
| JP2010508362A5 (cg-RX-API-DMAC7.html) | ||
| ES2564906T3 (es) | Inhibidores de NS5A del VHC | |
| JP2012523415A5 (cg-RX-API-DMAC7.html) | ||
| JP2010508360A5 (cg-RX-API-DMAC7.html) | ||
| JP2012533630A5 (cg-RX-API-DMAC7.html) | ||
| JP5808496B2 (ja) | 抗ウイルス化合物 | |
| CA2875690A1 (en) | Macrocyclic inhibitors of flaviviridae viruses | |
| JP2013517286A5 (cg-RX-API-DMAC7.html) | ||
| CN111433210A (zh) | 作为抗病毒药的稠合三环吡唑并-二氢吡嗪基-吡啶酮化合物 | |
| JP2011511841A5 (cg-RX-API-DMAC7.html) | ||
| JP2011511840A5 (cg-RX-API-DMAC7.html) | ||
| JP2015529652A5 (cg-RX-API-DMAC7.html) | ||
| WO2019097479A1 (en) | Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b | |
| JP2013533317A5 (cg-RX-API-DMAC7.html) |